{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T12:35:29Z","timestamp":1768739729193,"version":"3.49.0"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2013,11,8]],"date-time":"2013-11-08T00:00:00Z","timestamp":1383868800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1007\/s40263-013-0123-5","type":"journal-article","created":{"date-parts":[[2013,11,7]],"date-time":"2013-11-07T13:48:13Z","timestamp":1383832093000},"page":"1125-1142","source":"Crossref","is-referenced-by-count":27,"title":["Lacosamide: A Review of Its Use as Adjunctive Therapy in the Management of Partial-Onset Seizures"],"prefix":"10.1007","volume":"27","author":[{"given":"Sheridan M.","family":"Hoy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,11,8]]},"reference":[{"key":"123_CR1","unstructured":"National Institute for Health and Clinical Excellence. The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care (pharmacological update of clinical guideline 20). 2012. http:\/\/www.nice.org.uk\/nicemedia\/live\/13635\/57784\/57784.pdf . Accessed 21 Oct 2013."},{"issue":"4","key":"123_CR2","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/j.1528-1167.2010.02522.x","volume":"51","author":"AT Berg","year":"2010","unstructured":"Berg AT, Berkovic SF, Brodie MJ, et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005\u20132009. Epilepsia. 2010;51(4):676\u201385.","journal-title":"Epilepsia"},{"issue":"11","key":"123_CR3","doi-asserted-by":"crossref","first-page":"907","DOI":"10.2165\/11587900-000000000-00000","volume":"25","author":"E Perucca","year":"2011","unstructured":"Perucca E. The pharmacology of new antiepileptic drugs: does a novel mechanism of action really matter? CNS Drugs. 2011;25(11):907\u201312.","journal-title":"CNS Drugs"},{"issue":"5","key":"123_CR4","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1535-7511.2010.01379.x","volume":"10","author":"M Wong","year":"2010","unstructured":"Wong M. Too much inhibition leads to excitation in absence epilepsy. Epilepsy Curr. 2010;10(5):131\u20132.","journal-title":"Epilepsy Curr"},{"key":"123_CR5","unstructured":"Bromfield EB, Cavazos JE, Sirven JI (eds) An introduction to epilepsy. West Hartford (CT): American Epilepsy Society; 2006. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK2508\/ . Accessed 21 Oct 2013."},{"key":"123_CR6","unstructured":"European Medicines Agency. Vimpat (lacosamide): summary of product characteristics. 2013. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000863\/WC500050338.pdf . Accessed 21 Oct 2013."},{"issue":"4","key":"123_CR7","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2165\/00003495-200969040-00005","volume":"69","author":"SA Cross","year":"2009","unstructured":"Cross SA, Curran MP. Lacosamide: in partial-onset seizures. Drugs. 2009;69(4):449\u201359.","journal-title":"Drugs"},{"key":"123_CR8","unstructured":"UCB Inc. VIMPAT\u00ae (lacosamide): prescribing information. 2013. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/022253s024,022254s018,022255s010lbl.pdf . Accessed 21 Oct 2013."},{"issue":"1","key":"123_CR9","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1124\/mol.107.039867","volume":"73","author":"AC Errington","year":"2008","unstructured":"Errington AC, St\u00f6hr T, Heers C, et al. The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol Pharmacol. 2008;73(1):157\u201369.","journal-title":"Mol Pharmacol"},{"issue":"12","key":"123_CR10","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1007\/s11064-004-7025-3","volume":"29","author":"T Czech","year":"2004","unstructured":"Czech T, Yang J-W, Csaszar E, et al. Reduction of hippocampal collapsin response mediated protein-2 in patients with mesial temporal lobe epilepsy. Neurochem Res. 2004;29(12):2189\u201396.","journal-title":"Neurochem Res"},{"issue":"6","key":"123_CR11","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/j.1755-5949.2012.00313.x","volume":"18","author":"C Wolff","year":"2012","unstructured":"Wolff C, Carrington B, Varrin-Doyer M, et al. Drug binding assays do not reveal specific binding of lacosamide to collapsin response mediator protein 2 (CRMP-2). CNS Neurosci Ther. 2012;18(6):493\u2013500.","journal-title":"CNS Neurosci Ther"},{"issue":"1","key":"123_CR12","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2478\/s13380-011-0002-9","volume":"2","author":"Y Wang","year":"2011","unstructured":"Wang Y, Khanna R. Voltage-gated calcium channels are not affected by the novel anti-epileptic drug lacosamide. Transl Neurosci. 2011;2(1):13\u201322.","journal-title":"Transl Neurosci"},{"issue":"8","key":"123_CR13","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.neuropharm.2006.02.002","volume":"50","author":"AC Errington","year":"2006","unstructured":"Errington AC, Coyne L, St\u00f6hr T, et al. Seeking a mechanism of action for the novel anticonvulsant lacosamide. Neuropharmacology. 2006;50(8):1016\u201329.","journal-title":"Neuropharmacology"},{"issue":"1","key":"123_CR14","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1527-3458.2007.00001.x","volume":"13","author":"BK Beyreuther","year":"2007","unstructured":"Beyreuther BK, Freitag J, Heers C, et al. Lacosamide: a review of preclinical properties. CNS Drug Rev. 2007;13(1):21\u201342.","journal-title":"CNS Drug Rev"},{"issue":"7","key":"123_CR15","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1111\/epi.12237","volume":"54","author":"A Shandra","year":"2013","unstructured":"Shandra A, Shandra P, Kaschenko O, et al. Synergism of lacosamide with established antiepileptic drugs in the 6-Hz seizure model in mice. Epilepsia. 2013;54(7):1167\u201375.","journal-title":"Epilepsia"},{"issue":"Suppl 1","key":"123_CR16","first-page":"173","volume":"21","author":"E Iacopini","year":"2012","unstructured":"Iacopini E, Carnicelli L, Di Coscio E, et al. Effect of lacosamide on sleep-wake cycle of adult patients with drug-resistant partial onset epilepsy [abstract no. P517]. J Sleep Res. 2012;21(Suppl 1):173.","journal-title":"J Sleep Res"},{"issue":"1","key":"123_CR17","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.yebeh.2010.10.002","volume":"20","author":"J Novy","year":"2011","unstructured":"Novy J, Patsalos PN, Sander JW, et al. Lacosamide neurotoxicity associated with concomitant use of sodium channel-blocking antiepileptic drugs: a pharmacodynamic interaction? Epilepsy Behav. 2011;20(1):20\u20133.","journal-title":"Epilepsy Behav"},{"issue":"7","key":"123_CR18","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1111\/j.1528-1167.2007.01188.x","volume":"48","author":"E Ben-Menachem","year":"2007","unstructured":"Ben-Menachem E, Biton V, Jatuzis D, et al. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia. 2007;48(7):1308\u201317.","journal-title":"Epilepsia"},{"issue":"6","key":"123_CR19","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1111\/j.1528-1167.2009.02496.x","volume":"51","author":"S Chung","year":"2010","unstructured":"Chung S, Sperling MR, Biton V, et al. Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial. Epilepsia. 2010;51(6):958\u201367.","journal-title":"Epilepsia"},{"issue":"3","key":"123_CR20","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1528-1167.2008.01951.x","volume":"50","author":"P Hal\u00e1sz","year":"2009","unstructured":"Hal\u00e1sz P, K\u00e4lvi\u00e4inen R, Mazurkiewicz-Beldzi\u0144ska M, et al. Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial. Epilepsia. 2009;50(3):443\u201353.","journal-title":"Epilepsia"},{"issue":"1\u20132","key":"123_CR21","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1159\/000339077","volume":"90","author":"W Cawello","year":"2012","unstructured":"Cawello W, Bonn R, Boekens H. Bioequivalence of intravenous and oral formulations of the antiepileptic drug lacosamide. Pharmacology. 2012;90(1\u20132):40\u20136.","journal-title":"Pharmacology"},{"issue":"1","key":"123_CR22","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1528-1167.2012.03725.x","volume":"54","author":"W Cawello","year":"2013","unstructured":"Cawello W, B\u00f6kens H, Nickel B. Tolerability, pharmacokinetics, and bioequivalence of the tablet and syrup formulations of lacosamide in plasma, saliva, and urine: saliva as a surrogate of pharmacokinetics in the central compartment. Epilepsia. 2013;54(1):81\u20138.","journal-title":"Epilepsia"},{"issue":"3","key":"123_CR23","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.yebeh.2011.08.032","volume":"22","author":"B Hillenbrand","year":"2011","unstructured":"Hillenbrand B, Wisniewski I, J\u00fcrges U, et al. Add-on lacosamide: a retrospective study on the relationship between serum concentration, dosage, and adverse events. Epilepsy Behav. 2011;22(3):548\u201351.","journal-title":"Epilepsy Behav"},{"issue":"4","key":"123_CR24","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s13318-012-0093-x","volume":"37","author":"W Cawello","year":"2012","unstructured":"Cawello W, Boekens H, Bonn R. Absorption, disposition, metabolic fate and elimination of the anti-epileptic drug lacosamide in humans: mass balance following intravenous and oral administration. Eur J Drug Metab Pharmacokinet. 2012;37(4):241\u20138.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"10","key":"123_CR25","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s40262-013-0080-7","volume":"52","author":"W Cawello","year":"2013","unstructured":"Cawello W, Fuhr U, Hering U, et al. Impact of impaired renal function on the pharmacokinetics of the antiepileptic drug lacosamide. Clin Pharmacokinet. 2013;52(10):897\u2013906.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"123_CR26","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1177\/0091270009347675","volume":"50","author":"W Cawello","year":"2010","unstructured":"Cawello W, Nickel B, Eggert-Formella A. No pharmacokinetic interaction between lacosamide and carbamazepine in healthy volunteers. J Clin Pharmacol. 2010;50(4):459\u201371.","journal-title":"J Clin Pharmacol"},{"issue":"11","key":"123_CR27","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1177\/0091270011426875","volume":"52","author":"W Cawello","year":"2012","unstructured":"Cawello W, Bonn R. No pharmacokinetic interaction between lacosamide and valproic acid in healthy volunteers. J Clin Pharmacol. 2012;52(11):1739\u201348.","journal-title":"J Clin Pharmacol"},{"key":"123_CR28","doi-asserted-by":"crossref","unstructured":"Cawello W, Surmann E, Waitzinger J. Lacosamide has no effect on the enzymatic activity of CYP3A4 [abstract no. P01.076]. Neurology. 2012;78(Meeting Abstracts 1).","DOI":"10.1212\/WNL.78.1_MeetingAbstracts.P01.076"},{"issue":"7","key":"123_CR29","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1111\/epi.12192","volume":"54","author":"A Stockis","year":"2013","unstructured":"Stockis A, van Lier JJ, Cawello W, et al. Lack of effect of lacosamide on the pharmacokinetic and pharmacodynamic profiles of warfarin. Epilepsia. 2013;54(7):1161\u20136.","journal-title":"Epilepsia"},{"issue":"3","key":"123_CR30","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/epi.12085","volume":"54","author":"W Cawello","year":"2013","unstructured":"Cawello W, Rosenkranz B, Schmid B, et al. Pharmacodynamic and pharmacokinetic evaluation of coadministration of lacosamide and an oral contraceptive (levonorgestrel plus ethinylestradiol) in healthy female volunteers. Epilepsia. 2013;54(3):530\u20136.","journal-title":"Epilepsia"},{"key":"123_CR31","doi-asserted-by":"crossref","unstructured":"Fountain N, Staelens L, Tytgat D, et al. Low lacosamide plasma protein binding in lacosamide-naive patients [abstract no. P01.077]. Neurology. 2012;78(Meeting Abstracts 1).","DOI":"10.1212\/WNL.78.1_MeetingAbstracts.P01.077"},{"issue":"7","key":"123_CR32","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1111\/epi.12158","volume":"54","author":"C Zhang","year":"2013","unstructured":"Zhang C, Chanteux H, Zuo Z, et al. Potential role for human P-glycoprotein in the transport of lacosamide. Epilepsia. 2013;54(7):1154\u201360.","journal-title":"Epilepsia"},{"key":"123_CR33","first-page":"S33","volume":"70","author":"W Rosenfeld","year":"2011","unstructured":"Rosenfeld W, Fountain NB, Kaubrys G, et al. Lacosamide: long-term safety and efficacy in partial-onset seizures [abstract no. M713]. Ann Neurol. 2011;70:S33.","journal-title":"Ann Neurol"},{"issue":"3","key":"123_CR34","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/j.1528-1167.2012.03407.x","volume":"53","author":"A Husain","year":"2012","unstructured":"Husain A, Chung S, Faught E, et al. Long-term safety and efficacy in patients with uncontrolled partial-onset seizures treated with adjunctive lacosamide: results from a Phase III open-label extension trial. Epilepsia. 2012;53(3):521\u20138.","journal-title":"Epilepsia"},{"issue":"Suppl 6","key":"123_CR35","first-page":"156","volume":"52","author":"F Rosenow","year":"2011","unstructured":"Rosenow F, Kelemen A, Ben-Menachem E, et al. Long-term adjunctive lacosamide in patients with uncontrolled partial-onset seizures: results from the SP774 phase III open-label extension trial [abstract no. p505]. Epilepsia. 2011;52(Suppl 6):156.","journal-title":"Epilepsia"},{"issue":"3","key":"123_CR36","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/j.1528-1167.2007.01317.x","volume":"49","author":"V Biton","year":"2008","unstructured":"Biton V, Rosenfeld WE, Whitesides J, et al. Intravenous lacosamide as replacement for oral lacosamide in patients with partial-onset seizures. Epilepsia. 2008;49(3):418\u201324.","journal-title":"Epilepsia"},{"issue":"12","key":"123_CR37","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.2165\/11586830-000000000-00000","volume":"24","author":"S Chung","year":"2010","unstructured":"Chung S, Ben-Menachem E, Sperling MR, et al. Examining the clinical utility of lacosamide: pooled analyses of three phase II\/III clinical trials. CNS Drugs. 2010;24(12):1041\u201354.","journal-title":"CNS Drugs"},{"key":"123_CR38","doi-asserted-by":"crossref","unstructured":"McShea C, Polinkovsky M, Dimova S, et al. Early efficacy with adjunctive lacosamide treatment in patients with uncontrolled partial seizures: analysis of mean percentage of seizure-free days per week [abstract no. P07.172]. Neurology. 2013;80(Meeting Abstracts 1).","DOI":"10.1212\/WNL.80.7_supplement.P07.172"},{"issue":"12","key":"123_CR39","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.2165\/11587550-000000000-00000","volume":"24","author":"J-K Sake","year":"2010","unstructured":"Sake J-K, Hebert D, Isoj\u00e4rvi J, et al. A pooled analysis of lacosamide clinical trial data grouped by mechanism of action of concomitant antiepileptic drugs. CNS Drugs. 2010;24(12):1055\u201368.","journal-title":"CNS Drugs"},{"issue":"Suppl 10","key":"123_CR40","first-page":"113","volume":"50","author":"C Loge De La","year":"2009","unstructured":"De La Loge C, Cramer J, Borghs S, et al. Improvement in patient-reported outcomes seen in patients responding to lacosamide: pooled QOLIE-31, SSS and PGIC data from 3 Phase II\/III clinical trials [abstract no. p516]. Epilepsia. 2009;50(Suppl 10):113.","journal-title":"Epilepsia"},{"key":"123_CR41","unstructured":"Cramer J, de la Loge C, Borghs S, et al. Improvement in patient-reported outcomes seen in patients responding to lacosamide: pooled QOLIE-31, SSQ and PGIC data from 3 phase II\/III clinical trials [abstract no. P05.187]. 62nd Annual Meeting of the American Academy of Neurology; 10\u201317 Apr 2010; Toronto."},{"issue":"Suppl 5","key":"123_CR42","first-page":"7","volume":"53","author":"N Dcruz","year":"2012","unstructured":"Dcruz N, Doty P, McShea C, et al. Long-term treatment with adjunctive lacosamide for partial-onset seizures: an analysis of results from patients exposed only to approved doses [abstract no. 020]. Epilepsia. 2012;53(Suppl 5):7.","journal-title":"Epilepsia"},{"key":"123_CR43","doi-asserted-by":"crossref","unstructured":"Cramer J, Borghs S, De Backer M, et al. Improved seizure severity, health-related quality of life and health status reported by patients during long-term treatment with lacosamide: analysis of pooled open-label data [abstract no. 2.245]. Epilepsy Curr. 2012;12(Suppl 1).","DOI":"10.1212\/WNL.78.1_MeetingAbstracts.PD3.008"},{"key":"123_CR44","unstructured":"Stefan H, Kerling F, Steinhoff BJ. Lacosamide add-on treatment: results of open label 6\u00a0months follow-up [abstract no. P05.188]. 62nd Annual Meeting of the American Academy of Neurology, 10\u201317 Apr 2010, Toronto."},{"issue":"Suppl 5","key":"123_CR45","first-page":"192","volume":"53","author":"K Kelly","year":"2012","unstructured":"Kelly K, Stephen LJ, Parker P, et al. Adjunctive lacosamide in patients with uncontrolled focal epilepsy: interim analysis of a prospective audit [abstract no. p661]. Epilepsia. 2012;53(Suppl 5):192.","journal-title":"Epilepsia"},{"issue":"Suppl 5","key":"123_CR46","first-page":"185","volume":"53","author":"M Noack-Rink","year":"2012","unstructured":"Noack-Rink M, Mayer T, Arnold S, et al. Lacosamide as add-on to monotherapy in patients with partial-onset seizures: interim results of the post-marketing VITO-BA study (VIMPAT added to one baseline AED) [abstract no. p639]. Epilepsia. 2012;53(Suppl 5):185\u20136.","journal-title":"Epilepsia"},{"issue":"3","key":"123_CR47","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.yebeh.2011.11.026","volume":"23","author":"V Villanueva","year":"2012","unstructured":"Villanueva V, L\u00f3pez-Gom\u00e1riz E, L\u00f3pez-Trigo J, et al. Rational polytherapy with lacosamide in clinical practice: results of a Spanish cohort analysis RELACOVA. Epilepsy Behav. 2012;23(3):298\u2013304.","journal-title":"Epilepsy Behav"},{"key":"123_CR48","unstructured":"Kurth C, Steinhoff BJ. Long-term treatment of 107 patients with lacosamide: experience of the epilepsy centre Kork (Germany) [abstract no. 2.272]. Epilepsy Curr. 2012;12(Suppl 1)."},{"issue":"7","key":"123_CR49","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.seizure.2012.05.005","volume":"21","author":"L Flores","year":"2012","unstructured":"Flores L, Kemp S, Colbeck K, et al. Clinical experience with oral lacosamide as adjunctive therapy in adult patients with uncontrolled epilepsy: a multicentre study in epilepsy clinics in the United Kingdom (UK). Seizure. 2012;21(7):512\u20137.","journal-title":"Seizure"},{"issue":"1\u20132","key":"123_CR50","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.eplepsyres.2013.05.002","volume":"106","author":"J Novy","year":"2013","unstructured":"Novy J, Bartolini E, Bell GS, et al. Long-term retention of lacosamide in a large cohort of people with medically refractory epilepsy: a single centre evaluation. Epilepsy Res. 2013;106(1\u20132):250\u20136.","journal-title":"Epilepsy Res"},{"issue":"2","key":"123_CR51","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.yebeh.2013.07.024","volume":"29","author":"V Villanueva","year":"2013","unstructured":"Villanueva V, L\u00f3pez FJ, Serratosa JM, et al. Control of seizures in different stages of partial epilepsy: LACO-EXP, a Spanish retrospective study of lacosamide. Epilepsy Behav. 2013;29(2):349\u201356.","journal-title":"Epilepsy Behav"},{"issue":"Suppl 5","key":"123_CR52","first-page":"54","volume":"53","author":"RD Elwes","year":"2012","unstructured":"Elwes RD, Kemp S, Flores L, et al. Clinical experience with oral lacosamide as adjunctive therapy in adult patients with uncontrolled epilepsy: a multicentre study in epilepsy clinics in the United Kingdom [abstract no. p182]. Epilepsia. 2012;53(Suppl 5):54.","journal-title":"Epilepsia"},{"key":"123_CR53","unstructured":"Borghs S, De Backer M, Mueller K, et al. Improved seizure severity, health-related quality of life and health status reported by patients during long-term treatment with lacosamide [abstract no. 1.262]. Epilepsy Curr. 2011;11(Suppl 1)."},{"issue":"1","key":"123_CR54","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/nyas.12213","volume":"1291","author":"P Doty","year":"2013","unstructured":"Doty P, Hebert D, Mathy F-X, et al. Development of lacosamide for the treatment of partial-onset seizures. Ann N Y Acad Sci. 2013;1291(1):56\u201368.","journal-title":"Ann N Y Acad Sci"},{"key":"123_CR55","unstructured":"UCB Inc. An international open-label extension trial to determine safety and efficacy of long-term oral lacosamide (SPM 927) in patients with partial seizures [Clinical Trials.gov identifier NCT00515619]. US National Institutes of Health, ClinicalTrials.gov (online). 2011. http:\/\/clinicaltrials.gov\/ . Accessed 21 Oct 2013."},{"key":"123_CR56","unstructured":"Data on file, UCB Inc., 2013."},{"key":"123_CR57","unstructured":"European Medicines Agency. Assessment report: Vimpat (lacosamide). 2008. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/000863\/WC500050341.pdf . Accessed 21 Oct 2013."},{"key":"123_CR58","doi-asserted-by":"crossref","unstructured":"Proposal for revised clinical and electroencephalographic classification of epileptic seizures. From the Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia. 1981;22(4):489\u2013501.","DOI":"10.1111\/j.1528-1157.1981.tb06159.x"},{"key":"123_CR59","unstructured":"Rosenfeld W, Fountain N, Rosenow F, et al. Safety and tolerability of lacosamide: a summary of adverse events in epilepsy clinical trials [abstract no. 3.245]. 62nd Annual Meeting of the American Epilepsy Society, 5\u20139 Dec 2008, Seattle (WA)."},{"key":"123_CR60","unstructured":"Hebert D, Helmstaedter C, Kanner A, et al. Preliminary evaulation of the risk of cognitive adverse events in lacosamide clinical trials for adjunctive treatment of partial onset seizures [abstract no. 2.228]. 63rd Annual Meeting of the American Epilepsy Society, 4\u20138 Dec 2009, Boston (MA)."},{"issue":"6","key":"123_CR61","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/j.1528-1167.2009.02463.x","volume":"51","author":"G Krauss","year":"2010","unstructured":"Krauss G, Ben-Menachem E, Mameniskiene R, et al. Intravenous lacosamide as short-term replacement for oral lacosamide in partial-onset seizures. Epilepsia. 2010;51(6):951\u20137.","journal-title":"Epilepsia"},{"issue":"1","key":"123_CR62","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1528-1167.2012.03543.x","volume":"54","author":"NB Fountain","year":"2013","unstructured":"Fountain NB, Krauss G, Isojarvi J, et al. Safety and tolerability of adjunctive lacosamide intravenous loading dose in lacosamide-naive patients with partial-onset seizures. Epilepsia. 2013;54(1):58\u201365.","journal-title":"Epilepsia"},{"key":"123_CR63","unstructured":"UCB Inc. An open-label extension trial to determine tolerability and efficacy of long-term oral SPM 927 as adjunctive therapy in patients with partial seizures [Clinical Trials.gov identifier NCT00552305]. US National Institutes of Health, ClinicalTrials.gov (online). 2011. http:\/\/clinicaltrials.gov\/ . Accessed 21 Oct 2013."},{"issue":"4","key":"123_CR64","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2165\/11599240-000000000-00000","volume":"26","author":"S Simoens","year":"2012","unstructured":"Simoens S, De Naeyer L, Dedeken P. Cost effectiveness of lacosamide in the adjunctive treatment of patients with refractory focal epilepsy in Belgium. CNS Drugs. 2012;26(4):337\u201350.","journal-title":"CNS Drugs"},{"issue":"7","key":"123_CR65","doi-asserted-by":"crossref","first-page":"A392","DOI":"10.1016\/S1098-3015(11)72607-9","volume":"13","author":"H Benhaddi","year":"2010","unstructured":"Benhaddi H, Gunn A, Ferro B. Medico-economic evaluation of lacosamide adjunctive therapy in the treatment of patients with refractory epilepsy in Scotland and Spain [abstract no. PND26]. Value Health. 2010;13(7):A392.","journal-title":"Value Health"},{"issue":"7","key":"123_CR66","doi-asserted-by":"crossref","first-page":"A323","DOI":"10.1016\/j.jval.2011.08.500","volume":"14","author":"H Benhaddi","year":"2011","unstructured":"Benhaddi H, Poliakova Z. Cost-utility analysis of lacosamide adjunctive therapy in the treatment of patients with refractory in the Slovak Republic [abstract no. PND34]. Value Health. 2011;14(7):A323.","journal-title":"Value Health"},{"issue":"Suppl 10","key":"123_CR67","first-page":"97","volume":"50","author":"F Berggren","year":"2009","unstructured":"Berggren F, Bolin K, Germe M, et al. The cost-effectiveness of adjunctive treatment with lacosamide in patients with uncontrolled partial epilepsy [abstract no. p452]. Epilepsia. 2009;50(Suppl 10):97.","journal-title":"Epilepsia"},{"issue":"3","key":"123_CR68","doi-asserted-by":"crossref","first-page":"A109","DOI":"10.1016\/j.jval.2013.03.516","volume":"16","author":"H Benhaddi","year":"2013","unstructured":"Benhaddi H, Tabak G. Cost-effectiveness of lacosamide adjunctive therapy in the treatment of patients with refractory epilepsy in Turkey [abstract no. PND48]. Value Health. 2013;16(3):A109.","journal-title":"Value Health"},{"key":"123_CR69","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2147\/NDT.S32081","volume":"9","author":"VD Nunes","year":"2013","unstructured":"Nunes VD, Sawyer L, Neilson J, et al. Profile of lacosamide and its role in the long-term treatment of epilepsy: a perspective from the updated NICE guideline. Neuropsychiatr Dis Treat. 2013;9:467\u201376.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"123_CR70","unstructured":"Benhaddi H, Vicente C, Tam R. Cost-utility analysis of lacosamide adjunctive therapy in the treatment of patients with refractory epilepsy in Canada [abstract no. 3.260]. 66th Annual Meeting of the American Epilepsy Society, 30 Nov\u20134 Dec 2012, San Diego (CA)."},{"issue":"3","key":"123_CR71","doi-asserted-by":"crossref","first-page":"A206","DOI":"10.1016\/j.jval.2011.02.1137","volume":"14","author":"H Benhaddi","year":"2011","unstructured":"Benhaddi H, Helmers S. Medico-economic evaluation of lacosamide adjunctive therapy in the treatment of patients with refractory epilepsy in the United States [abstract no. PND27]. Value Health. 2011;14(3):A206\u20137.","journal-title":"Value Health"},{"issue":"2","key":"123_CR72","doi-asserted-by":"crossref","first-page":"199","DOI":"10.2165\/00003495-200969020-00005","volume":"69","author":"MA Stein","year":"2009","unstructured":"Stein MA, Kanner AM. Management of newly diagnosed epilepsy: a practical guide to monotherapy. Drugs. 2009;69(2):199\u2013222.","journal-title":"Drugs"},{"key":"123_CR73","unstructured":"National Institute for Health and Clinical Excellence. The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care (NICE clinical guideline 137). 2012. http:\/\/www.nice.org.uk\/nicemedia\/live\/13635\/57779\/57779.pdf . Accessed 21 Oct 2013."},{"key":"123_CR74","unstructured":"UCB Inc. A historical-controlled, multicenter, double-blind, randomized trial to assess the efficacy and safety of conversion to lacosamide 400\u00a0mg\/day monotherapy in subjects with partial-onset seizures. [Clinical Trials.gov identifier NCT00520741]. US National Institutes of Health, ClinicalTrials.gov (online). 2012. http:\/\/clinicaltrials.gov\/ . Accessed 21 Oct 2013."},{"key":"123_CR75","unstructured":"UCB Inc. A multicenter, open-label extension trial to assess the long-term use of lacosamide monotherapy and safety of lacosamide monotherapy and adjunctive therapy in subjects with partial-onset seizures [Clinical Trials.gov identifier NCT00530855]. US National Institutes of Health, ClinicalTrials.gov (online). 2013. Accessed 21 Oct 2013."},{"issue":"1","key":"123_CR76","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1528-1167.2012.03688.x","volume":"54","author":"M Mula","year":"2013","unstructured":"Mula M, Kanner AM, Schmitz B, et al. Antiepileptic drugs and suicidality: an expert consensus statement from the Task Force on Therapeutic Strategies of the ILAE Commission on Neuropsychobiology. Epilepsia. 2013;54(1):199\u2013203.","journal-title":"Epilepsia"},{"issue":"7","key":"123_CR77","doi-asserted-by":"crossref","first-page":"555","DOI":"10.2165\/00002018-200730070-00001","volume":"30","author":"M Mula","year":"2007","unstructured":"Mula M, Sander JW. Negative effects of antiepileptic drugs on mood in patients with epilepsy. Drug Saf. 2007;30(7):555\u201367.","journal-title":"Drug Saf"},{"issue":"6","key":"123_CR78","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s40263-013-0063-0","volume":"27","author":"A Gaitatzis","year":"2013","unstructured":"Gaitatzis A, Sander JW. The long-term safety of antiepileptic drugs. CNS Drugs. 2013;27(6):435\u201355.","journal-title":"CNS Drugs"},{"key":"123_CR79","unstructured":"Isojarvi J, Williams C, Doty P. Outcome of infants with prenatal exposure to lacosamide during the clinical development program [abstract no. P05.180]. 62nd Annual Meeting of the American Academy of Neurology, 10\u201317 Apr 2010, Toronto."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-013-0123-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-013-0123-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-013-0123-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,19]],"date-time":"2024-05-19T08:15:50Z","timestamp":1716106550000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-013-0123-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,8]]},"references-count":79,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["123"],"URL":"https:\/\/doi.org\/10.1007\/s40263-013-0123-5","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,8]]}}}